Suppl. Figure 5. The effect of long term use of rIT86 on the EGFRvIII-expressing xenografts. A: The effect of rIT86 on the A549-EGFRvIII xenografts when rIT86 was first administered when the xenografts reached the average size of 158 mm3. rIT86, 70 µg/kg b.w. in 100 µL saline was injected i.v., once daily for 5 consecutive days (n = 7), and the same volume of saline was used as control (n = 7), as indicated with red arrowheads from Day 1 to 5, followed by treatment at 7 µg/kg b.w., once daily as indicated by green arrowheads until Day 28. \* indicates P < 0.01; # indicates P < 0.01 comparing to controls (Student’s t test). B: The effect of rIT86 on the A549-EGFRvIII xenografts when rIT86 was first administered when the xenografts reached the average size of 358 mm3. rIT86, 50 µg/kg b.w. in 100 µL saline was injected i.v., once daily for 12 consecutive days (n = 5), and the same volume of saline was used as control (n = 7), as indicated with blue arrowhead from Day 1, followed by treatment at 30 µg/kg b.w., twice daily as indicated by red arrow on Day 13 until Day 21. C: The effect of rIT86 on the MDA-MB231-EGFRvIII xenografts when rIT86 was first administered when the xenografts reached the average size of 229 mm3. rIT86, 50 µg/kg b.w., in 100 µL saline was injected i.v., once daily for 5 consecutive days (n = 7), and the same volume of saline was used as control (n = 9), as indicated with red arrowheads from Day 1 to 5, followed by treatment at 25 µg/kg b.w., once daily as indicated by blue/green arrowheads until Day 28. \* indicates P < 0.05; + indicates P < 0.01 comparing to controls (Student’s t test). D: The effect of rIT86 on the MDA-MB231-EGFRvIII xenografts when rIT86 was first administered when the xenografts reached the average size of 138 mm3. rIT86, 50 µg/kg b.w. in 100 µL saline was injected i.v., once daily from Day 1 for 27 consecutive days (n = 9), and the same volume of saline was used as control (n = 8). \* indicates P < 0.05; # indicates P < 0.01 comparing to controls (Student’s t test). E: The effect of rIT86 on the Du145-EGFRvIII xenografts. rIT86, 50 µg/kg b.w. in 100 µL saline was injected i.v., once daily for 5 consecutive days when the Du145-EGFRvIII xenografts reached the average size of 479 mm3 (n = 11), and the same volume of saline was used as control (n = 14, average size of 220 mm3) from Day 1 to 5, followed by treatment at 25 µg/kg b.w., once daily as indicated by blue/green arrows until Day 28. \* indicates P < 0.05 comparing to controls (Student’s t test). F: The effect of rIT86 on the Du145-EGFRvIII xenografts when rIT86 was first administered when the xenografts reached the average size of 200 mm3. rIT86, 50 µg/kg b.w. in 100 µL saline was injected i.v., once daily from Day1 for 27 consecutive days (n = 8), and the same volume of saline was used as control (n = 8). \* indicates P < 0.05 comparing to controls (Student’s t test).

